Do incentives from Big Pharma influence the way doctors treat cancer patients? A study published earlier this year in JAMA Oncology says YES.
The first study to evaluate reimbursement policies and clinical care in oncology, the review found that oncologists often change their treatment recommendations and prescriptions based on incentives from the pharmaceutical industry.
July 09, 2017 by: Isabelle Z
(Natural News) Fentanyl is the most powerful opioid that has ever been mass-marketed. Quick to kick in and powerful enough to conquer pain that other opioids couldn’t touch, it was designed with the intention of helping cancer patients die comfortably. Why, then, is this “heroin on steroids” given out to patients in New Jersey for routine operations like tonsil removal?
According to NJ.com, the answer is simple: money. Common sense says that oncologists should be the ones prescribing such a powerful and dangerous drug, but an investigation by New Jersey Advance Media revealed that in the Garden State, eight different medical specialties filed more claims with Medicare for fentanyl than cancer doctors. This includes family practitioners, who filed more than five times the number of fentanyl claims from 2013 to 2015 than oncologists did. Even nurse practitioners and physicians’ assistants were heavy prescribers…